Table 2 Univariate analysis of risk factors for oxaliplatin-induced vascular pain
Vascular pain (+) | Vascular pain (−) | Odds ratio | 95%CI | P value | ||
|---|---|---|---|---|---|---|
Incidence (%) | n = 124 | n = 66 | ||||
Gender | ||||||
Female | 64.4 | 47 | 26 | 0.94 | 0.51–1.73 | 0.876 |
Male | 65.8 | 77 | 40 | |||
Age | ||||||
≧ 70 | 62.1 | 41 | 25 | 0.81 | 0.43–1.51 | 0.526 |
< 70 | 66.9 | 83 | 41 | |||
BMI | ||||||
≧ 22 | 58.2 | 53 | 38 | 0.55 | 0.30–1.01 | 0.067 |
< 22 | 71.7 | 71 | 28 | |||
Clinical stage | ||||||
IV | 56.8 | 46 | 35 | 0.52 | 0.29–0.96 | 0.045 |
I-III | 71.6 | 78 | 31 | |||
History of chemotherapy | ||||||
2nd | 41.2 | 7 | 10 | 0.34 | 0.12–0.93 | 0.035 |
1st | 67.6 | 117 | 56 | |||
L-OHP dosage | ||||||
< 130 mg/m2 | 57.1 | 56 | 42 | 0.47 | 0.25–0.87 | 0.022 |
130 mg/m2 | 73.9 | 68 | 24 | |||
Solution volume mixed with oxaliplatin | ||||||
500 mL | 67.2 | 41 | 20 | 1.14 | 0.60–2.17 | 0.746 |
250 mL | 64.3 | 83 | 46 | |||
Warming the injection site | ||||||
Yes | 63.3 | 81 | 47 | 0.76 | 0.40–1.46 | 0.516 |
No | 69.4 | 43 | 19 | |||
Analgesics | ||||||
Yes | 56.3 | 9 | 7 | 0.66 | 0.23–1.86 | 0.425 |
No | 66.1 | 115 | 59 | |||
Opioids | ||||||
Yes | 62.5 | 5 | 3 | 0.88 | 0.20–3.81 | 1.000 |
No | 65.4 | 119 | 63 | |||
Non-opioids | ||||||
Yes | 54.5 | 6 | 5 | 0.62 | 0.18–2.12 | 0.519 |
No | 65.9 | 118 | 61 | |||
pH adjustment (addition of dexamethasone to infusion solution mixed with oxaliplatin) | ||||||
Yes | 78.3 | 18 | 5 | 2.07 | 0.73–5.86 | 0.242 |
No | 63.5 | 106 | 61 | |||